Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncology area due to the mounting evidence of their potential to provide promising therapeutic options for patients. Herein, we describe the discovery strategy to overcome the issues inherent in lead structure 1 that resulted in the identification of Smoothened inhibitor 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (PF-04449913, 26), which has been advanced to human clinical studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025788 | PMC |
| http://dx.doi.org/10.1021/ml2002423 | DOI Listing |
Publication Analysis
Top Keywords
discovery pf-04449913
4
pf-04449913 potent
4
potent orally
4
orally bioavailable
4
bioavailable inhibitor
4
inhibitor smoothened
4
smoothened inhibitors
4
inhibitors hedgehog
4
hedgehog signaling
4
signaling pathway
4